37 results about "Therapeutic Hormone" patented technology

New and improved compounds for use in diagnostic imaging or therapy having the formula M-N—O—P-G, wherein M is a metal chelator having the structure:

wherein R1-R5 and FG are as defined herein (in the form complexed with a metal radionuclide or not), N—O—P is the linker containing at least one non-alpha amino acid with a cyclic group, at least one substituted bile acid or at least one non-alpha amino acid, and G is the GRP receptor targeting peptide. In the preferred embodiment, M is an Aazta metal chelator or a derivative thereof.

Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided. Novel methods of treating prostate tumors or of delaying the progression of prostate tumors are also provided, including, methods of treating bone or soft tissue metastases of prostate cancer, methods for treating hormone sensitive and hormone refractory prostate cancer, methods for delaying the progression of hormone sensitive prostate cancer, for facilitating combination therapy in patients with hormone sensitive prostate cancer and for decreasing aberrant vascular permeability in patients with hormone sensitive prostate cancer.

The invention relates to the use of non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment and prophylaxis of hormone-dependent, particularly estrogen-dependent, diseases. The invention further relates to suitable inhibitors and to a method for the production thereof.

Method for screening for a non-hormone agent potentially useful to treat a hormone disorder The method involves contacting a potential agent with a system containing a cellular component and a translation factor. The component and factor interact with one another in an intact normal cell in a manner responsive to the hormone to cause a modulation of translation in the cell. The method involves determining whether the agent causes a modulation of translation by the component and the factor analogous to that which occurs in intact cells in response to the hormone.

Methods for treating hormone associated conditions, such as endometriosis, uterine leiomata, ovarian cancer, breast cancer, or vaginal bleeding, using LHRH antagonists and selective estrogen receptor modulators are disclosed. The methods include administering to a subject a combination of an LHRH antagonist and a selective estrogen receptor modulator. Pharmaceutical compositions and kits for use in the methods of the invention are also provided.

The present invention relates to methods and uses for preventing or treating hormone-dependent diseases, in particular breast cancer, in a mammal, by a combination of an progesterone-receptor antagonist, in particular the progesterone-receptor antagonist 11β-(4-acetylphenyl)-17β-hydroxy-17α-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue thereof, and a pure antiestrogen, in particular a compound of general formula I as defined in the specification, for instance 11β-Fluoro-17α-methyl-7α-{5-[methyl(8,8,9,9,9-pentafluorononyl)amino]pentyl}-estra-1,3,5(10)-triene-3,17β-diol. The invention further relates to pharmaceutical compositions comprising said combination.

The present invention comprises the design, synthesis and development of a new class of chemotherapeutic agents for prophylactic and therapeutic treatments in a mammal, particularly a human, believed to be at risk of suffering from a hormone-responsive disorder. In an aspect of the invention, such treatments include therapeutic compositions comprising novel steroidal antiestrogen and antiandrogen compounds. In a preferred aspect, such a novel compound of the present invention has an address and a message component, which are made into a single composite entity for more aggressive intervention and effective treatment of hormone-responsive disorders, thereby prolonging the disease-free interval for the patient and reducing a number of side effects.

The invention provides a pharmaceutical composition for treating corticosteroid-dependent dermatitis and a preparation method thereof. The pharmaceutical composition comprises, by weight, 4-6 parts of white mulberry root bark, 2-4 parts of fritillaria cirrhosa, 2-4 parts of angelica sinensis, 2-4 parts of fructus kochiae, 4-6 parts of radix sophorae flavescentis, 2-4 parts of fleece-flower root, 0.5-1.5 parts of chrysanthemum, 0.5-1.5 parts of honeysuckle, 0.5-1.5 parts of pseudo-ginseng flower, 2-4 parts of motherwort, 0.5-1.5 parts of ganoderma lucidum and 0.5-1.5 parts of wild ginseng. The pharmaceutical composition has the advantages that the pharmaceutical composition has effects of clearing away heat and toxic materials, activating blood and relieving swelling, purging fire for removing toxic materials and activating blood circulation to dissipate stasis and can be effectively used for treating the corticosteroid-dependent dermatitis.

The present disclosure provides industrially scalable methods of making (Z)-endoxifen or a salt thereof, crystalline forms of endoxifen, and compositions comprising them. The present disclosure also provides methods for treating hormone-dependent breast and hormone-dependent reproductive tract disorders.

A method and apparatus for measuring binding between a plurality of molecules of a biological receptor protein and a plurality of molecules of a type which binds to said biological receptor is presented. Apparatus utilizes a sensor possessing a waveguide to which have been attached in close proximity to its surface, features resembling molecules having binding affinity for said biological receptor. Light is injected into said waveguide so as to produce an evanescent field at its surface. Molecules of receptor protein are tagged with a tag belonging to that class of chemicals which alters a characteristic of light, when said light passes through said chemical tag. Apparatus utilizes a rapid means of monitoring the change in optical signal coming from the waveguide as binding proceeds between tagged receptor protein and the binding molecular feature of the waveguide. This allows direct measurement of binding and dissociation rates between the receptor and the binding feature of the waveguide. By using a waveguide having a feature resembling a ligand for the receptor, the potential hormonal activity of a test substance may be evaluated from its ability to compete with the waveguide for binding with the receptor. The effect of a test compound on binding of receptor protein to a subsequent element in a hormonal signal transduction mechanism is evaluated by measuring the impact of the test compound on binding between receptor protein and a feature resembling said next element of the signal transduction mechanism. Methods are provided whereby such data may be used to compute affinity constants, binding activity, complex affinity constants resulting from cooperativity, and kinetic parameters for the receptor and test ligand and for the receptor and the next element of the signal transduction mechanism. Preferred embodiments of the invention illustrate application of the method and apparatus to measuring binding between biological receptors and their nuclear response elements, and the use of this type of measurement for assessment of the activity of estrogen mimics present in a test sample, and for evaluation of pharmaceuticals intended to treat hormone dependent cancers.

The invention provides a moisturizing cream suitable for atopic dermatitis of children. According to the moisturizing cream, a lactobacillus fermentation product is applied to skin moisturizing cosmetics for adjuvant treatment of children atopic dermatitis for the first time, and then allantoin, an oat extract, ceramide, phytosterol, fatty acid, glycyrrhizic acid, glycyrrhizate, hesperidin, grease and a moisturizer are used as auxiliary materials; and the moisturizing cream prepared by the invention has a remarkable curative effect on atopic dermatitis, can regulate the skin micro-ecological environment and improve the phenomena of severe skin itching, dry skin and the like, improves the safety under the condition of ensuring the curative effect of the medicine on the atopic dermatitis, and does not irritate the skin of children. The moisturizing cream disclosed by the invention can be used for assisting in treating the atopic dermatitis of children, the dosage of treatment hormone is reduced, and the stimulation caused by the treatment hormone is effectively relieved.

The invention belongs to the technical field of biology and new medicine, and particularly relates to a composition for treating hormone face and acne skin, the composition comprises the following active ingredients: hyaluronic acid, glycerol, vitamin B, trehalose and stem cell culture supernatant, and the stem cell culture supernatant is derived from human umbilical cord mesenchymal stem cells. The preparation method of the composition comprises the following steps: (1) calculating and weighing the hyaluronic acid, the glycerol, the vitamin B, the trehalose and the stem cell culture supernatant according to the mass percentage contents of 1 to 3%, 2 to 6%, 0.1 to 2%, 2 to 20% and 20 to 30% respectively, and supplementing the balance of sterilized water for injection to 100%; and (2) fully mixing the components, and aseptically filling the mixture into a 2ml sterile heat-source-free pipe. The invention has the beneficial effects that the product takes effect for a short time, can treat various skin problems, and is high in effective rate and not easy to relapse.

The invention discloses application of lipoxin in treating hormone-dependent type asthma. Glucocorticoids become preferred drugs for asthma treatment and play important roles in controlling the asthma, but hormone-dependent type asthma patients are necessary to use the glucocorticoids in quantity for a long time so that intracorporal glucocorticoid receptors are down regulated and reduced in affinity, therefore the inhibition of the airway inflammation is affected and the asthma is recurrent and protractedly cured. The lipoxin can enhance the sensibility of the hormone-dependent type asthma patients on hormones by inhibiting related multidrug resisting proteins, thereby enhancing the curative effect on treating the asthma through the hormones and reducing the dosage and the side effect of the hormones; and in addition, the invention provides a new treatment method for the hormone-dependent type asthma.

The invention provides a traditional Chinese medicine preparation for treating hormone-dependent dermatitis and a preparation method of the traditional Chinese medicine preparation. The preparation method comprises the following steps: crushing natural Chinese herbal medicines, and respectively extracting the crushed natural Chinese herbal medicines for three times by using cold water which is 5 times, 7 times and 10 times of the dry weight of the medicines to obtain first extract liquor and first filter residues; extracting the first filter residues for three times by using hot water which is2 times, 4 times and 6 times of the dry weight of the medicines to obtain second extract liquor; respectively filtering the first extract liquor and the second extract liquor by using a filter element with the aperture of 0.5-1 microns to obtain first filtrate and second filtrate, and merging the first filtrate and the second filtrate; performing centrifugal treatment on the filtrate, and reserving supernate; and concentrating the supernate at low temperature, and preparing the concentrate into powder to obtain the traditional Chinese medicine preparation. The preparation method of the traditional Chinese medicine preparation for treating the hormone-dependent dermatitis is high in extraction efficiency, and the relative content of the extracted effective components is high. Moreover, various operations are conventional, no technical operation threshold exists, and the traditional Chinese medicine preparation for treating the hormone-dependent dermatitis and the preparation method ofthe traditional Chinese medicine preparation are suitable for popularization and industrialization.

The invention relates to an analysis method of hyssopus officinalis volatile oil and application of the hyssopus officinalis volatile oil in preparation of a medicine for treating hormone-resistant asthma, which comprises qualitative and relative quantitative analysis of chemical components of the hyssopus officinalis volatile oil, construction of a hormone-resistant asthma model and grouped administration. The influence of the hyssopus officinalis volatile oil on the number of inflammatory cells in alveolar lavage fluid and peripheral blood of a mouse with the hormone-resistant asthma is researched, and the influence of the hyssopus officinalis volatile oil on the concentration of interleukin-17 (IL-17) and granulocyte colony stimulating factor (G-CSF) in BALF and lung tissues of the mouse with the hormone-resistant asthma is researched. The influence of the hyssopus officinalis volatile oil on pathological changes of lung tissues of mice with hormone-resistant asthma is studied, and the chemical components of the hyssopus officinalis volatile oil and the pharmacological action of the hyssopus officinalis volatile oil for treating the hormone-resistant asthma are integrally evaluated according to the studies. The hyssopus officinalis volatile oil has great significance in new drug research and clinical application of the hyssopus officinalis volatile oil for treating the hormone-resistant asthma.

The present disclosure provides a novel topical composition comprising at least one active agent and method for making the composition. Certain compounds have been combined to make a stable composition comprising at least one active agent such as selective estrogen receptor modulators and aromatase inhibitors. The present disclosure also provides methods for treatment of hormone-dependent breast and hormone-dependent reproductive tract disorders.

The present disclosure provides tetra-substituted cyclobutane inhibitors of Androgen Receptor Action, and methods of using such inhibitors, for the treatment of hormone-refractory cancers.

A method and composition for the treatment of hormone allergy is disclosed. The method relates to using progesterone dilutions, or any other steroid hormone, to treat the systemic symptoms of hormone allergy, including pain. The composition of the hormone dilutions ranges from 10⁻¹ to 10⁻⁵. The hormone dilution may be administered sublingually, or, in the alternative, an intradermal route of administration may be chosen. Hormone dilutions may be administered at daily intervals or on any other treatment schedule as required to alleviate a patient's symptoms.

The present invention provides benzamide compounds, compositions containing said benzamides and the use of benzamides for inhibiting androgen receptor (AR) and/or aldoketo reductase family 1 member C3 (AKR1C3). Also described herein are methods of treating hormone-mediated diseases and conditions, including hormone-associated cancers, such as castration-resistant prostate cancer.